Bing Han | Medicine and Dentistry | Outstanding Scientist Award

Posted on by Phenomenological Research Awards

Dr.Bing Han | Medicine and Dentistry | Outstanding Scientist Award 

Dermatologist at The First Hospital of Jilin University | China

Dr. Bing Han is a medical researcher and clinician specializing in dermatological science with a strong foundation in advanced medical education and academic training. Dr. Bing Han has extensive professional experience integrating clinical practice with translational research, focusing on melanoma, vitiligo, and molecular mechanisms of skin disease progression. The research interests emphasize biomarker discovery, metabolic reprogramming, and therapeutic innovation in dermatology. With 99 scholarly documents, 1,291 citations from 1,231 documents, and an h-index of 22, Dr. Bing Han demonstrates sustained scientific impact and excellence in medical research.

Citation Metrics (Scopus)

1400

1000

600

200

0

Citations
1,291

Documents
99

h-index
22


View Scopus Profile

Featured Publications

Taeyoung Kyong | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research Awards

Dr. Taeyoung Kyong | Medicine and Dentistry | Research Excellence Award 

Professor at Yonsei University College of Medicine | South Korea

Dr. Taeyoung Kyong is a medical academic and clinician recognized for expertise in hospital medicine and inpatient care. His education and professional training underpin a strong foundation in internal medicine and clinical research. He has extensive experience integrating patient-centered practice with system-based healthcare improvement. His research interests focus on hospitalist-led care models, diabetes management, quality improvement, and digital health applications. Overall, Dr. Taeyoung Kyong’s work reflects a sustained commitment to advancing evidence-based inpatient medicine and healthcare excellence.

View ORCID

Featured Publications

Rolf Teschke | Medicine and Dentistry | Best Paper Award

Posted on by Phenomenological Research Awards

Prof. Rolf Teschke | Medicine and Dentistry | Best Paper Award

Professor at Klinikum Hanau | Germany

Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.

Profile; Scopus | Orcid

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.

Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.

Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.

Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.

Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Posted on by Phenomenological Research Awards

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.

Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica

 

Barbara Ariue | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Barbara Ariue | Medicine and Dentistry | Best Researcher Award 

Dr. Barbara Ariue is a distinguished medical professional and academic leader specializing in pediatric allergy and immunology, recognized for her outstanding contributions to research, education, and clinical innovation. As an Associate Professor of Pediatrics at a leading medical institution, she has dedicated her career to advancing the understanding and management of pediatric asthma, allergic conditions, stinging insect allergies, and immunodeficiency disorders. Her academic journey reflects a deep commitment to excellence in both teaching and scientific inquiry, inspiring medical students and resident physicians to pursue evidence-based and compassionate patient care. Dr. Barbara Ariue’s research has significantly impacted the field, particularly through her pioneering project, “Addressing Knowledge Gaps in Diagnosing and Managing Inborn Errors of Immunity,” which received a planning grant from the Allergists’ Foundation Community Grant Program under the American College of Allergy, Asthma, and Immunology. The project evaluates diagnostic practices, interdisciplinary collaboration, and educational needs in managing immunodeficiencies, leading to her recent publication, “Lessons from the ACAAI Survey: Advancing the Diagnostic and Therapeutic Strategies for the Practicing Allergist-Immunologist,” in the Annals of Allergy, Asthma, and Immunology. Her scholarly output includes publications in prestigious journals such as Journal of Clinical Immunology, Pediatrics, and Biochemical and Biophysical Research Communications. In addition to her research, she serves as a consultant and advisory board member for various pharmaceutical organizations, contributing her expertise to clinical trials and therapeutic advancements in immunology. Professionally, she holds fellowships and leadership positions in numerous medical societies, including the American College of Allergy, Asthma, and Immunology, and the American Academy of Pediatrics, reflecting her influence in shaping professional standards in allergy and immunology. Her citation index demonstrates 168 citations by 168 documents, with 11 publications and an h-index of 6, underscoring the impact and reach of her scientific work. Dr. Barbara Ariue’s career embodies a balance of clinical dedication, academic leadership, and research excellence, with her contributions continually shaping the future of pediatric immunology and fostering global advancements in medical science and patient care.

Profile: Scopus | Orcid  

Featured Publications:

  • Oh, C. K., Ariue, B., Alban, R. F., Shaw, B., & Cho, S. H. (2002). PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and Biophysical Research Communications, 294(5), 1155–1160.

  • Heimall, J., Keller, M., Saltzman, R., Bunin, N., McDonald-McGinn, D., Ariue, B., … Markert, M. L. (2012). Diagnosis of 22q11.2 deletion syndrome and Artemis deficiency in two children with T-B-NK+ immunodeficiency. Journal of Clinical Immunology, 32(5), 1141–1144.

  • Cho, S. H., Hall, I. P., Wheatley, A., Ariue, B. K., Abraha, D., Delmundo, J., & Oh, C. K. (2001). The possible role of plasminogen activator inhibitor-1 gene in the development of asthma. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K., Cho, S. H., Tam, S. W., & Oh, C. K. (2001). 142 Analysis of airway remodeling genes in human mast cells by cDNA microarrays. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 43 – Anaphylaxis (in book chapter). In Pediatrics. Mosby Inc.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 48 – Insect allergies (in book chapter). In Pediatrics. Mosby Inc.

  • McDonnell, J., Angarola, B., Ariue, B., Arnold, D. E., Assa’ad, A. H., Aytekin, C., … Bleesing, J. (2024). COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs: a USIDNET report. Journal of Clinical Immunology.

Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award 

Assistant professor at Beth Israel Deaconess Medical Center | United States

Dr. Zsuzsanna Zsengeller is a distinguished medical scientist whose career spans clinical medicine, molecular biology, and translational research. She has established herself as a global leader in the investigation of preeclampsia, mitochondrial dysfunction, and kidney-related disorders. With appointments at world-renowned institutions, she has advanced knowledge in gene therapy, molecular signaling, and maternal-fetal health. Her professional journey demonstrates a seamless integration of clinical insight and laboratory research, producing innovative therapeutic approaches. Through consistent scholarly output, grant leadership, and mentorship of future scientists, Dr. Zsuzsanna Zsengeller embodies excellence in academic medicine and translational science, with her work directly impacting patient health worldwide.

Profile:

Orcid

Education:

Dr. Zsuzsanna Zsengeller earned her Doctor of Medicine degree in General Medicine, followed by a Ph.D. in Medical Science with a strong foundation in microbiology. Her academic path was marked by a commitment to understanding complex disease mechanisms through both experimental and clinical approaches. Her postgraduate training included prestigious postdoctoral fellowships in pulmonary biology and respiratory diseases, where she refined her expertise in molecular and cellular biology. These academic experiences provided the groundwork for her lifelong research into oxidative stress, immune signaling, and vascular biology, ultimately shaping her into a well-recognized expert in mitochondrial and maternal health research.

Experience:

Dr. Zsuzsanna Zsengeller has extensive experience as both a clinician and scientist, having held positions across leading hospitals, research institutions, and industry collaborations. Her work includes significant contributions to pulmonary biology, renal pathology, and preeclampsia research. She has served in roles as staff scientist, senior scientist, consultant, and academic faculty member, currently serving as Assistant Professor of Medicine at Harvard Medical School. Her collaborations with multidisciplinary teams have resulted in advancements in therapeutic strategies for cardiovascular, renal, and maternal health. With experience in academia, industry, and clinical translation, she has built a unique career that bridges discovery and application.

Research Interest:

Dr. Zsuzsanna Zsengeller’s research interests center on the pathogenesis and treatment of preeclampsia, kidney disease, and mitochondrial dysfunction. She investigates redox biology, nitric oxide modulation, and oxidative stress pathways to understand how cellular signaling impacts maternal and fetal outcomes. Her translational studies have examined novel dual-function redox modulators, antioxidants, and mitochondrial-targeted therapies. Beyond maternal health, her work extends into nephrology and cardiovascular disease, with particular focus on mechanisms of APOL nephropathy and endothelial dysfunction. Through advanced molecular techniques and therapeutic modeling, her research seeks to translate laboratory discoveries into clinical strategies, offering hope for improved patient outcomes worldwide.

Awards and Honors:

Dr. Zsuzsanna Zsengeller has been recognized with numerous honors that reflect her leadership in biomedical science and translational medicine. She has received institutional research funding awards, including competitive support for her pioneering work on mitochondrial-targeted antioxidants for preeclampsia therapy. Her contributions have also been acknowledged through awards from scientific societies, highlighting her excellence in poster presentations, mentorship, and innovative project design. Her research projects have consistently received funding from federal agencies and medical foundations, underscoring the clinical relevance and impact of her work. These awards honor her as a trailblazer in developing therapies addressing urgent global health challenges.

Publications:

Title: Development of Diaryl Hydrazones for Alleviation of Mitochondrial Oxidative Stress in Preeclampsia
Year of Publication: 2025
Citation: 1

Title: Gasdermin D deletion prevents liver injury and exacerbates extrahepatic damage in a murine model of alcohol-induced ACLF
Year of Publication: 2025
Citation: 1

Title: A Novel Multi-organ Male Model of Alcohol-induced Acute-on-chronic Liver Failure Reveals NET-mediated Hepatocellular Death, Which is Prevented by RIPK3 Inhibition
Year of Publication: 2025
Citation: 5

Title: Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2
Year of Publication: 2024
Citation: 5

Title: Solvent- and Catalyst-Free Environmentally Benign High Hydrostatic Pressure-Assisted Synthesis of Bioactive Hydrazones and the Evaluation of Their Stability Under Various Storage Conditions
Year of Publication: 2024
Citation: 3

Title: A Novel Dual-Function Nitric Oxide Donor Therapy for Preeclampsia—A Proof-of-Principle Study in a Murine Model
Year of Publication: 2023
Citation: 3

Title: Hepatocyte nuclear factor 4α mediated quinolinate phosphoribosylltransferase (QPRT) expression in the kidney facilitates resilience against acute kidney injury
Year of Publication: 2023
Citation: 8

Conclusion:

Dr. Zsuzsanna  Zsengeller stands as a pioneering physician-scientist whose research has transformed the understanding of oxidative stress, mitochondrial dysfunction, and maternal-fetal disorders. Her leadership in translational medicine continues to advance new therapies that address major public health burdens, particularly preeclampsia and kidney disease. Through groundbreaking research, impactful publications, and mentorship of future leaders, she exemplifies the highest standards of academic and clinical excellence. Her career demonstrates how dedication to discovery can be translated into real-world medical advancements, making her a highly deserving candidate for prestigious recognition in biomedical and clinical research innovation.